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1. Introduction 
 Obesity has turned into a global epidemic which was earlier present in developed countries but has started to 
spread in developing countries as well [1,2]. According to WHO, 1.6 billion people are overweight out of which 400 
million are obese [3].Obesity itself can lead to various metabolic, cardiovascular and/or pulmonary disorders [4].Obesity is 
defined by the WHO based on the BMI of a person. BMI is calculated using weight in kg and height in meter. The BMI is 
calculated by the following formula:
 
BMI= weight (kg)/height (m)
2 
According to WHO, obesity is classified by the values obtained by the BMI. If a person’s BMI is <18.5kg/m2 they 
are considered underweight, 18.6-24.99kg/m
2
 is normal and >25kg/m
2
 is overweight. The overweight is again stratified into 
4 classes as shown in Table 1. 
Table 1: Classification of overweight based on BMI 
Overweight BMI 
Pre-obesity 25 to 29.99 kg/m
2
 
Obesity class l 30 to 34.99 kg/m
2
 
Obesity class ll 35 to 39.99 kg/m
2
 
Obesity class lll >40 kg/m
2
 
When the BMI is more than 40kg/m
2, it’s known as morbid obesity [5]. Accurate dosage regimens for obese 
patients are still vague. The pharmacokinetics of each person varies with a change in weight. As the number of obese 
patients with comorbidities such as diabetes mellitus and hypertension increases, physicians will encounter more problems 
regarding doses as the normal dose may not show therapeutic effect. The clearance and distribution of obese patients are 
different from a normal person [6-10].
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2. Pharmacokinetics 
The pharmacokinetics of an obese person is different from a normal person. If we understand them the calculation 
of dose might be more accurate and easier. 
2.1 Absorption:  
Absorption depends on the lipophilicity of the drug. Adipose tissue does not affect the absorption. Studies show 
that there is no major alteration in the absorption in obese patients [11-14].
 
2.2 Distribution:  
Lipophilic drugs show increased volume of distribution than lipophobic or hydrophilic drugs as they are 
distributed in the fat tissue and the lean mass. For example volume of distribution of Benzodiazepines is high [15,16]. 
Hence TBW should be used. According to various studies, IBW should be used in case of hydrophilic drugs because the 
distribution is only limited to the lean tissue. Hence the distribution of both kinds of drugs varies greatly making it more 
difficult to obtain the correct dose [17-19]. 
2.3 Metabolism: 
Increased level of serum proteins changes the metabolism in obese patients that leads to different half-lives of the 
drug in an obese patient from a normal person [20]. An increase in phase ll metabolism is noticed. Phase l metabolism 
either increases or remains the same [21]. 
2.4 Excretion:  
Liver and kidney are the most important organs for the excretion of the drug. Any change in the physiology may 
affect the clearance of the drug. In some cases, obesity can cause fatty liver which impairs the blood flow. That creates an 
impact on the clearance in the liver [22]. According to Han et al obese patients exhibit higher clearance than non-obese 
[23]. The kidney weight, renal blood flow glomerular filtration rate is higher in obese people hence clearance is high [24]. 
In an attempt to calculate the dosage regimen various formulae or dosing scales have been formulated. Ideally the dosing 
formula should consider height, weight, pharmacokinetic factors etc but so far that kind of formula doesn’t yet exist yet 
[25]. It is mandatory that whenever medications are administered to an obese patient, especially the ones with narrow 
therapeutic index, he or she should be monitored closely. Some of the commonly used parameters for dose calculation 
include: 
Body mass index (BMI): As explained before, BMI is officially used to obtain dosage regimens. According to Michael J 
Henley et al BMI is not the most appropriate dosing scalar because it does not consider adipose tissue and lean body mass 
separately [26].
 
Body Surface Area (BSA): It is calculated using height, weight and constants as [27]: 
BSA (m)
2
= [(TBW)×(height in cm)/3600]
1/2
 
BSA is extensively used in dosing of anti-cancer agents, however its use in calculating drug dose in obese patients 
is still questionable [28]. Just like BMI, BSA cannot differentiate between adipose tissue and lean body mass [28]. 
Total Body Weight: This method is usually used for normal patients [29]. Lean body mass and fat depositions do not 
increase proportionally in morbidly obese patients [30]. Since majority of the blood supply is goes to regular muscles 
instead of adipose tissue, using this method for calculation may cause toxicity in morbidly obese patients [29]. 
Ideal Body Weight (IBW): Its equation is based on size which relates it to mortality of a subject.  An empirical equation to 
estimate IBW was derived by Devine [31]: 
IBW (kg) = 45.4 kg (49.9 kg if male) + 0.89 × (height in cm– 152.4) 
IBW is different from BMI and BSA because it considers gender while calculating. The use of ideal body weight is 
limited because it implies that patients with same height should receive the same dose and the changes occurring in the 
body due to obesity [29].
 
Lean Body Weight (LBW): It is the weight of a person devoid of all the fat mass. It does not take the weight of the 
adipose tissue into consideration [26].LBW (kg) = (9270 × TBW)/(A + B×BMI), where values of A and B are 6680 and 216 
for males, and 8780 and 244 for females [30]. 
Predicted Normal Weight: It is used to predict the normal weight of an obese individual [32]. It is usually not accurate 
when height and weight are extreme [33]. 
For males, PNWT (kg) = 1.57 ×TBW- 0.0183 ×BMI ×TBW- 10.5. 
For females, PNWT (kg) = 1.75 ×TBW - 0.0242 ×BMI ×TBW - 12.6 
A compilation of drug list along with the formulae that can be used to calculate dosage regimens is depicted in 
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Table 2. 
Table 2: Drugs with formulae to calculate dosage regimens 
Drug Formula 
Anaesthetic 
Propofol [34-37] 
Induction: IBW 
Induction: LBW assessed by BIA 
Maintenance: TBW or 
IBW + 0.4 excess weight 
Thiopental [38,39] 
7.5 mg/kg IBW 
TBW 
Lidocaine [40] IBW 
Ketamine [41] IBW 
Anti- depressant 
Midazolam [42,43] 
TBW for initial dose 
IBW for continuous dose 
Lorazepam [44] 
Loading doses should be adjusted on actual weight and maintenance doses should be adjusted on 
ideal body weight. 
Benzodiazepine [45] IBW 
Skeletal muscle relaxants 
Vecuronium [46] IBW 
Cisatracurium[47] 
TBW 
IBW 
Rocuronium[48] IBW 
Succinylcholine [49] TBW 
Atracurium [50] IBW or ABW 
Muscle stimulants 
Neostigmine [51] TBW 
Suggamadex [52] IBW + 40% excess weight 
Analgesics 
Alfentanil [12,53,54] 
IBW 
or corrected weight 
TBW 
Fentanyl [55-57] 
TBW 
Corrected weight = IBW + (0.4x excess weight) 
pharmacokinetic mass = 52/[1 + (196.4 9 e-0.025kg – 53.66)/100] 
Sufentanil [58,59] TBW 
Remifentanil [12,60] 
LBM (James equation) 
LBM (Janmahasatian equation) 
Morphine [61] IBW 
Paracetamol [62] IBW 
Opiates [45] IBW 
Anti-viral 
Acyclovir [40] IBW 
Ganciclovir [40] ABW 
Anti-fungal 
Amphotericin B [63] TBW 
Fluconazole [64] TBW 
Flucytosine[65] IBW 
Anidulafungin[40] 
Loading dose: 200 mg 
Maintenance dose: 100 mg 
Antibiotics 
Erythromycin [66] IBW 
Daptomycin[64] TBW 
Penicillins[67] TBW 
Carbapenem[45] TBW 
Cephalosporin [45] TBW 
Ciprofloxacin [68,69] (0.45 [TBW-IBW]) + IBW 
Gentamicin [68] (0.4 [TBW-IBW]) + IBW 
Amikacin [45] (0.4 [TBW-IBW]) + IBW 
Vancomycin [68] TBW 
Tobramycin [68] (0.4 [TBW-IBW]) + IBW 
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Clindamycin [70] Maximum of 4.8g/day in divided doses 
Metronidazole [71] 500mg TDS 
Anti-tubercular 
Ethambutol[40] IBW 
Isoniazid [40] IBW 
Pyrazinamde[40] IBW 
Rifampin [72] IBW 
Anticoagulants 
Heparin [73,74] ABW 
Lepirudin [40] TBW (Use actual body weight up to 110 kg) 
Warfarin [75] ABW 
Enoxaparin [76] TBW 
Argatroban[77] TBW 
Anti-epileptics 
Phenytoin [78] Dosing weight= IBW+[1.33(ABW-IBW)] 
Valproic Acid [79] IBW 
Carbamazepine [45] IBW 
Cardiovascular drugs 
Procainamide [40] IBW 
Digoxin [45] IBW 
Anti- neoplastic agents 
Busulphan [80] BSA 
Cyclophosphamide [81] Adj Body Weight= IBW+40%(TBW-IBW) 
Melphalan [40] BSA 
Thiotepa[81] Adj Body Weight= IBW+40%(TBW-IBW) 
Carboplatin [81] Adj Body Weight= IBW+40%(TBW-IBW) 
Doxorubicin [11] BSA 
Topotecan [11] BSA 
Irinotecan[11] BSA 
Cisplatin [11] BSA 
Paclitaxel [11] BSA 
Docetaxel[11] BSA 
Methotrexate [82] BSA 
Miscellaneous 
Cyclosporine [83] IBW 
Theophylline [40] IBW 
Immunoglobulin [7] Dose Determining Weight= IBW+0.4[actual body weight(kg)- IBW] 
G-CSF (Filgrastim) [40] Actual Body Weight 
 
3. Conclusion 
Various scales have been formulated to calculate drug dosing in obese population but more research needs to be 
done to get precise doses. 
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